BioSpace News Archive

Deals

Novo Nordisk A/S: Share repurchase programme - November 25, 2019

On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.

November 27, 2019
·
2 min read
Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

Kiadis Pharma N.V., a clinical stage biopharmaceutical company, announces that Kiadis will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference.

November 27, 2019
·
3 min read
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

Myovant Sciences announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 10:35 a.m. Eastern Time in Boston, MA.

November 27, 2019
·
1 min read
Drug Development

GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH

Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data

November 27, 2019
·
8 min read
Bio NC

G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019

G1 Therapeutics, Inc., a clinical-stage oncology company, announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference.

November 27, 2019
·
1 min read
Biotech Bay

Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

Satsuma Pharmaceuticals, Inc. announced that John Kollins, Satsuma President and Chief Executive Officer, will present a corporate update at the Evercore ISI HealthCONx Investor Conference, taking place December 3-5, 2019 in Boston.

November 27, 2019
·
1 min read
Genetown

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that the company will participate in the following upcoming investor conferences in December

November 27, 2019
·
1 min read
Drug Development

Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

November 27, 2019
·
7 min read
Pharm Country

Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference

Ovid Therapeutics Inc. announced that Amit Rakhit, M.D., President and Chief Medical Officer, will participate in an analyst-led fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 4:00 p.m. EST.

November 27, 2019
·
1 min read
Genetown

Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 8:20 a.m. ET in Boston, MA..

November 27, 2019
·
1 min read